UNSPSC 51343810: Atazanavir/ritonavir and lamivudine/zidovudine

This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, ATAZANAVIR, has a US FDA Unique Ingredient Identifier of QZU4H47A3S. The second component, RITONAVIR, has a US FDA Unique Ingredient Identifier of O3J8G9O825. The third component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The fourth component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.

UNSPSC 51343810 Atazanavir/ritonavir and lamivudine/zidovudine (Commodity) does not align with recent state and local procurement activity. The code nominally covers specific antiretroviral pharmaceutical products, yet the opportunities posted under this code span emergency medical services mobile applications, long-term care facility pharmaceutical services, pharmacy benefits programs, naloxone distribution and drug deactivation systems, forensic drug standards, and procurement conference attendance—none of which involve the specified antiretroviral drugs. The single opportunity tangentially related to the code's pharmaceutical scope is Dane County's RFP for comprehensive pharmaceutical services to Badger Prairie Health Care Center (proposals due October 22, 2026), which encompasses general medication distribution, dispensing, and management for a long-term care facility rather than antiretroviral therapy. The geographic spread across the opportunities reflects Florida (Collier County, Clay County, Palm Bay, Seminole County, Marion County, Pinellas County), Wisconsin (Dane County), Oregon (Washington County), Kentucky (Owensboro), California (San Mateo County), Arizona (Tucson), Texas (West Texas Centers), and Washington DC, but this dispersion does not indicate meaningful procurement activity under the antiretroviral code itself.

State and local bodies posting opportunities under UNSPSC 51343810 appear to be health departments, counties with medical centers or long-term care facilities, and specialized health agencies, though the code assignment itself does not reflect their actual purchasing intent. Issuing bodies include Dane County (long-term care pharmaceutical services RFP), Collier County (EMS mobile application Notice of Intent), West Texas Centers for Mental Health and Mental Retardation (prescription and pharmacy services RFP due August 21, 2026), and the District of Columbia (pharmacy benefits program network qualification request due October 7, 2026). Because the procurement notices under this code do not solicit antiretroviral drugs or related products matching the code's definition, activity under UNSPSC 51343810 does not represent a viable procurement category for vendors supplying atazanavir/ritonavir and lamivudine/zidovudine.